Medically Supervised Withdrawal for Opioid Dependence

  • Sanford M. SilvermanEmail author


Medically supervised withdrawal from opioids can be accomplished with a variety of pharmacologic techniques. The use of agonists, antagonists, and partial agonists are widely utilized in practice today. Clonidine has been used historically to manage the adrenergic (autonomic) symptoms of opioid withdrawal. Methadone has been the gold standard for opioid agonist therapy (OAT) and is rapidly being replaced by sublingual buprenorphine. This treatment is available for the primary care physician upon fulfilling certain requirements to utilize sublingual buprenorphine. As the prescription drug epidemic continues, it is important for the practitioner to recognize the overlap between chronic pain and opioid dependence, as well as the treatment of both.


Sublingual buprenorphine Opioid dependence Medically supervised withdrawal Drug Addiction Treatment Act Clonidine Methadone Prescription drug abuse Office-based opioid detoxification 


  1. 1.
    Manchikanti L, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I—evidence assessment. Pain Physician. 2012;15:S1–66.PubMedGoogle Scholar
  2. 2.
    Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten year perspective. Pain Physician. 2010;13:401–35.PubMedGoogle Scholar
  3. 3.
    Volkow ND, McLellan TA, Cotto JH. Characteristics of opioid prescriptions in 2009. JAMA. 2011;305:1299–301.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Governale L. Outpatient prescription opioid utilization in the U.S., years 2000–2009. Drug Utilization Data Analysis Team Leader, Division of Epidemiology, Office of Surveillance and Epidemiology. Presentation for U.S. Food and Drug Administration, 22 July 2010.Google Scholar
  5. 5.
    IMS Institute for Healthcare Informatics. The use of medicines in the United States: Review of 2011; April 2012.Google Scholar
  6. 6.
    Report of the International Narcotics Control Board 2008. New York: United Nations.
  7. 7.
    Broward County Commission on Substance Abuse. Based on data from the Broward County Appraisal Office and Automation of Reports and Consolidated Orders System (ARCOS); 2009.Google Scholar
  8. 8.
    Automation of Reports and Consolidated Orders System (ARCOS). US Drug Enforcement Agency; 2010.Google Scholar
  9. 9.
    Adopted by the American Society of Addiction Medicine Board of Directors; 4/12/2011.Google Scholar
  10. 10.
    Gold M, Redmond DE, Kleber HD. Clonidine blocks acute opioid withdrawal symptoms. Lancet. 1978;1:929–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679–84.PubMedGoogle Scholar
  12. 12.
    Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract. 1982;19(3):276–88.CrossRefGoogle Scholar
  13. 13.
    Wesson DR, Ling W. The Clinical Opioid Withdrawal Scale. J Psychoactive Drugs. 2003;35:253–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Zubieta JK, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000;23(3):326–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Kakko J, et al. Buprenorphine improved treatment retention in patients with heroin dependence. Lancet. 2003;361:662–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Jones HE, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Ling W, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090–100.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest. 2003;33:824–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Ling W, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997;70(2–3):109–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Comprehensive Pain MedicineFlorida Society of Interventional Pain Physicians (FSIPP)Pompano BeachUSA

Personalised recommendations